血流导向装置治疗颅内动脉瘤:DIVERSION全国前瞻性队列研究
DIVERSION研究为法国全国前瞻性队列,纳入2012年10月至2014年2月所有血流导向装置置入患者。12个月无事件生存率为75.7%,满意闭塞率79.9%,永久相关严重事件率5.9%,死亡率1.2%。
要点
- 血流导向装置12个月满意闭塞率近80%,但无事件生存率仅75.7%。
- 永久相关严重事件率5.9%,12个月死亡率1.2%。
- 基线高血压、糖尿病和较大动脉瘤与神经功能缺损发生相关。
核心结论
- 血流导向装置治疗后12个月满意闭塞率近80%,永久相关严重事件率和死亡率分别为5.9%和1.2%。
研究设计与样本
- DIVERSION为法国全国前瞻性队列研究,纳入2012年10月至2014年2月所有血流导向装置置入病例,共398例患者477个颅内动脉瘤。
主要发现
- 408次介入中95次发生至少1次死亡或疾病事件,12个月无事件生存率75.7%(95%CI 71.1-79.7)。
- 12个月永久相关严重事件率为5.9%,死亡率为1.2%。
- 12个月满意闭塞率为79.9%。
- 基线高血压(HR 2.54,95%CI 1.35-4.79,P=0.039)、糖尿病(HR 3.70,95%CI 1.60-8.6,P=0.0022)和较大动脉瘤(HR 1.07,95%CI 1.04-1.11,P<0.0001)与神经功能缺损发生相关。
- 无基线高血压(OR 2.01,95%CI 1.12-3.71,P=0.0193)和术后满意闭塞(OR 2.75,95%CI 1.49-5.09,P=0.0012)与12个月满意闭塞相关。
关键数值与推荐
- 满意闭塞定义为12个月时独立影像核心实验室按Kamran量表评为3或4级。
- 主要终点为12个月无事件生存率,事件包括颅内出血、缺血性卒中、非脑出血、占位效应所致神经功能缺损、再治疗或死亡。
临床怎么用
- 血流导向装置可用于颅内动脉瘤的血管内治疗,但需权衡12个月内的疾病事件风险。
- 基线高血压、糖尿病和较大动脉瘤患者应加强围手术期风险评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Flow diverters are used for endovascular therapy of intracranial aneurysms. We did a nationwide prospective study to investigate the safety and effectiveness of flow diversion at 12 months. Methods- DIVERSION was a national prospective cohort study including all flow diverters placement between October 2012 and February 2014 in France. The primary end point was the event-free survival rate at 12 months, defined as the occurrence of morbidity (intracranial hemorrhage, ischemic stroke, noncerebral hemorrhage, or neurological deficit due to mass effect), retreatment, or death within 12 months post-treatment. A quality control was carried out on 100% of the collected data and of at least 10% of the included patients in each center, chosen at random. All reported serious events were adjudicated by an independent Data Safety and Monitoring Board. Satisfactory occlusion was defined as 3 or 4 on Kamran scale by an independent imaging core laboratory at 12 months. Results- We enrolled 398 patients harboring 477 intracranial aneurysms. At least 1 morbidity-mortality event was noted in 95 of 408 interventions representing an event-free survival rate of 75.7% (95% CI, 71.1-79.7). The rate of permanent-related serious events and mortality was 5.9% and 1.2% at 12 months, respectively. Multivariate analysis showed that high baseline blood pressure (hazard ratio, 2.54; 95% CI, 1.35-4.79; P=0.039), diabetes mellitus (hazard ratio, 3.70; 95% CI, 1.60-8.6; P=0.0022), and larger aneurysms (hazard ratio, 1.07; 95% CI, 1.04-1.11; P<0.0001) were associated with the occurrence of a neurological deficit. The satisfactory occlusion rate at 12 months was 79.9%, and the absence of high baseline blood pressure (odds ratio, 2.01; 95% CI, 1.12-3.71; P=0.0193) and postprocedural satisfactory occlusion (odds ratio, 2.75; 95% CI, 1.49-5.09; P=0.0012) were associated with a 12-month satisfactory occlusion. Conclusions- A satisfactory occlusion was achieved in almost 80% of cases after flow diverter treatment with a permanent-related serious event and mortality rates of 5.9% and 1.2% at 12 months, respectively.
引用
- Gory B, Berge J, Bonafé A, et al. Flow Diverters for Intracranial Aneurysms: The DIVERSION National Prospective Cohort Study. Stroke. 2019. PMID: 31765296. doi:10.1161/STROKEAHA.119.024722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。